The only takeaways from the below article are that BigPharma are criminally insane, and they have completely captured the FDA, while the Useless CDC and WHO are aiding and abetting these crimes against humanity along with the governments that are all in on this depopulation and control program.
This is global biofascism by an emboldened One World Government positioned to harm societies with “free” slow kill bioweapon injectables that the victims are paying for via the very tax theft that they should never pay in the first place.
When the DEATHVAX™ survivor tax donkey debt-slaves are finally drained of their disposable incomes and savings they will have little choice but to link their social credit score apps to their UBI which will require the State sanctioned thinking and behaving along with more deadly “vaccine” compliance. And it is now painfully clear that all of the DEATHVAX™ offerings (more than 70 various injections to date) do less than zero in terms of inoculation, while inducing a plethora of adverse reactions, shortened lifespans and death.
The fact that they are aggressively going after babies that they know have an IFR of zero for PSYOP-19 or any other “viral” infection by generating fraudulent and goal-seeked in-house “studies” proves criminal intent; for all parties engaged in this latest murderous scheme.
by
“A total of 13 participants withdrew from the study (9 BNT162b2 recipients and 4 placebo recipients).” Ok.
“Participants 6-23 months of age Among participants 6-23 months of age, 3 BNT162b2 recipients and no placebo recipients withdrew from the study due to an AE. One BNT162b2 recipient developed fever (>40°C) 2 days post-Dose 1 that resolved in 3 days, with concurrent exanthema subitem (viral infection) that resolved in 4 days. Another BNT162b2 recipient with a history of eczema developed a generalized rash 5 days after receiving Dose 1, which resolved by Day 9. Additionally, 1 BNT162b2 recipient reported pyrexia 3 days post Dose 3 that resolved in 3 days.” Hmm. Ok. Exanthema subitem! Nice words. Makes me feel stupid. How about you?
6.3. Known and potential risks
In study participants 6 months through 4 years of age, there were numerically higher rates of solicited local and systemic ARs in BNT162b2 recipients than in placebo recipients.
Really? That’s surprising.
One 6-month-old BNT162b2 recipient was reported to have an SAE of seizure (eye rolling upwards) that occurred 2 days after Dose 2, preceded by symptoms of a respiratory tract infection and temperature of 38.0°C. The participant was evaluated in the emergency department and admitted to the hospital for evaluation of seizure: with eye rolling upwards noted once on an otherwise normal physical/neurological examination.
Watch this movie and this movie for a specific story of what happened to a young infant that suffered this same AE following injection.
Convulsions were reported at a similar incidence in the BNT162b2 (n=4, 0.3%) and placebo (n=1, 0.2%) groups. These included: 2 events of seizure in the BNT162b2 group, one of which occurred 3 days post-Dose 2 and was reported as an SAE (Section 4.2.7.5), and the other was a nonserious event with onset 164 days post-Dose 2; and 2 events of febrile convulsion in the BNT162b2 group, one of which was reported as an SAE (Section 4.2.7.5), and both of which occurred >30 days after vaccination. All were considered by the study investigator and by FDA as not related to study intervention.
Convulsions. Seizures. Wow. That sounds pretty bad considering we’re talking about infants so young they have barely ‘learned’ to hold their own heads up.
Participants 6-23 months of age Among participants 6-23 months of age, SAEs were reported in 17 (3.1%) participants in the BNT162b2 group and 14 (2.3%) in the placebo group, most of which were gastrointestinal or respiratory illnesses/infections that occur commonly in this age group. SAEs reported in the BNT162b2 group included RSV bronchiolitis (5 participants), pneumonia (2 participants), gastroenteritis (2 participants), lower respiratory tract infection (2 participants), and the following events were each reported once (a participant can report more than one event): anal abscess, anaphylaxis, lower respiratory tract infection, viral lower respiratory tract infection, metapneumovirus infection, rhinovirus infection, rotavirus gastroenteritis, viral gastroenteritis, accidental overdose, febrile convulsion, seizure. None of the SAEs in the BNT162b2 group were considered by the study investigator or by FDA to be related to vaccination, given the time to onset after vaccination and/or plausible alternate etiology.
Gastrointestinal eh? Isn’t that how they described Maddie de Garay’s AEs?
I have so many more screenshots to show you but there’s no need. Enough. The data is sparse, lamentable, has a terribly useless efficacy assessment, terrible safety profile… What more do we need?
I mean, look at the rates in the red box. 61% of the infants experienced and reported a reaction within 7 days following Dose 1? Really? And how the hell is that 58.2% of the infants injected with placebo experienced a reaction as well? Are we talking about ‘injection site redness’ or something more serious? Because, last time I checked, ‘systemic’ meant ‘everywhere’. Right? It seems that no, they checked the ‘injection site reaction’ and those rates were about half the systemic rates. And what of the SAE (Severe Adverse Events) rates? I am sorry but I have to ask because it does not make sense to me. Why and how would 2.3/100 (or 1/43) infants on the placebo experience an SAE? Huh?
And even if we forget we saw that and focused on the SAE rate for the BNT162b2 3 ug arm, 1.4/100 (1/71) infants suffered a SEVERE ADVERSE EVENT? WHAT IN THE HOLY HELL? Oh and don’t forget, they only checked 1,178 infants. For the purposes of injecting millions.
Here’s a similar poster for you to print and distribute. We have one day left. And then the rest of our lives.
Do NOT comply.
